ABVC Biopharma Inc
ABVC
查看详细走势图
2.190USD
+0.150+7.35%
收盘 12/19, 16:00（美东）报价延迟15分钟
52.98M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.35%
5天
+3.79%
1月
-17.67%
6月
+19.02%
今年开始到现在
+271.19%
1年
+317.94%
查看详细走势图
TradingKey ABVC Biopharma Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
ABVC Biopharma Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名208/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
ABVC Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ABVC Biopharma Inc亮点
亮点风险
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
ABVC Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ABVC Biopharma Inc简介
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
公司代码ABVC
公司ABVC Biopharma Inc
CEOPatil (Uttam Yashwant)
网址https://abvcpharma.com/
常见问题
ABVC Biopharma Inc(ABVC)的当前股价是多少？
ABVC Biopharma Inc(ABVC)的当前股价是 2.190。
ABVC Biopharma Inc的股票代码是什么？
ABVC Biopharma Inc的股票代码是ABVC。
ABVC Biopharma Inc股票的52周最高点是多少？
ABVC Biopharma Inc股票的52周最高点是5.480。
ABVC Biopharma Inc股票的52周最低点是多少？
ABVC Biopharma Inc股票的52周最低点是0.400。
ABVC Biopharma Inc的市值是多少？
ABVC Biopharma Inc的市值是52.98M。
ABVC Biopharma Inc的净利润是多少？
ABVC Biopharma Inc的净利润为-4.90M。
现在ABVC Biopharma Inc(ABVC)的股票是买入、持有还是卖出？
根据分析师评级，ABVC Biopharma Inc(ABVC)的总体评级为--，目标价格为--。
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是多少
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是-0.280。
相关品种
